ClinicalTrials.Veeva

Menu

Early Identification of Subclinical Atherosclerosis Using Non-Invasive Imaging Research (EISNER)

Cedars-Sinai Medical Center logo

Cedars-Sinai Medical Center

Status

Completed

Conditions

Coronary Artery Disease
Atherosclerosis

Treatments

Other: Coronary Artery Calcium (CAC) Scan

Study type

Interventional

Funder types

Other

Identifiers

Details and patient eligibility

About

Early Identification of Subclinical Atherosclerosis by Noninvasive Imaging Research (EISNER) is a multi-study research program being conducted at Cedars-Sinai Medical Center.

The principal objective of this randomized trial (referred to as "Study 1") is to assess whether coronary artery calcium (CAC) scanning provides clinical benefit thus improving patient outcomes in asymptomatic subjects with intermediate coronary artery disease (CAD) risk. Additionally, the study is designed to assess the value of combining the CAC scan with the Framingham risk score (FRS) and measurements of serum or plasma biomarkers to predict outcomes.

Full description

At baseline eligible subjects underwent a clinic visit where they were randomized 2:1 to a "scan group" which had complete cardiac risk assessment and CAC scanning or a "no scan group" which had only complete cardiac risk assessment. Both groups underwent a private counseling session with a trained nurse practitioner to review their results and receive customized health behavior suggestions based on current American Heart Association guidelines for primary prevention of heart disease.

Subjects were followed up for changes in clinical status, medication use and specific health behaviors at one year after baseline. Annually for four years, subjects were followed up for subsequent diagnostic testing, therapy, and outcomes related to their cardiac health.

At four years after baseline, all subjects (from both groups) returned for a repeat clinic visit to have a complete cardiac risk assessment and CAC scanning. Year 4 CAC scanning was performed in both the "scan group" and "no scan group".

Additional long-term followup is being conducted under a separate protocol.

Enrollment

2,137 patients

Sex

All

Ages

45 to 80 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • No symptoms of CAD

  • Intermediate risk of CAD, defined as either:

    1. male with age of 55-80 years or female with age 65-80 years or

    2. male of 45-54 years and at least one CAD risk factor or female with age 55-64 years and at least one CAD risk factor

      • Risk factors include: smoking, high blood pressure, high total or LDL cholesterol, low HDL cholesterol, diabetes, family history of early CAD.)

Exclusion criteria

  • History of CVD including heart attack, cardiomyopathy, peripheral artery disease, angina, revascularization, and CVA (stroke)
  • Prior coronary calcium scan or coronary angiogram
  • Pregnancy
  • Required radiation badges for work (CSMC Radiation Safety ruling)
  • Clinically unstable health status or significant medical co-morbidity

Trial design

Primary purpose

Prevention

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

None (Open label)

2,137 participants in 2 patient groups

Scan group
Experimental group
Description:
"Scan" group undergoes complete cardiac risk assessment and CAC scanning at baseline.
Treatment:
Other: Coronary Artery Calcium (CAC) Scan
No scan group
No Intervention group
Description:
"No scan" group undergoes only complete cardiac risk assessment (without CAC scan) at baseline.

Trial contacts and locations

1

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems